Michael P. Pantze

The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions

Jürg Reichen, Christoph Funk, Bruno Stieger, 2001, Clinical pharmacology and therapeutics.

Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.

C. Funk, C. Ponelle, G. Scheuermann, 2001, Molecular pharmacology.

The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition

B. Lum, H. Jones, A. Rakhit, 2007, European Journal of Clinical Pharmacology.

METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS

C. Prakash, B. Lum, A. Rakhit, 2006, Drug Metabolism and Disposition.

Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer

R. Plummer, M. Ranson, C. Twelves, 2014, Anti-cancer drugs.

Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration

T. Singer, D. Danilenko, F. Theil, 2012, mAbs.

Pharmacokinetics and metabolism of the dipeptidyl peptidase IV inhibitor carmegliptin in rats, dogs, and monkeys

C. Funk, M. Zell, O. Kuhlmann, 2010, Xenobiotica; the fate of foreign compounds in biological systems.

Anti-inflammatory properties of docosahexaenoic and eicosapentaenoic acids in phorbol-ester-induced mouse ear inflammation.

D. Raederstorff, M. Pantze, U. Moser, 1996, International archives of allergy and immunology.